TRxADE HEALTH INC
For the period ended Dec 31, 2023. Filed Apr 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 22, 2024
SCNX$3.20+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
December 31, 2023 and 2022
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current Assets | ||
| Cash | $151,908 | $1,094,894 |
| Accounts receivable, net | 821,804 | 629,921 |
| Inventory | 968 | 65,523 |
| Prepaid assets | 107,774 | 104,461 |
| Notes receivable | 1,300,000 | - |
| Other receivables | 370,608 | - |
| Current assets of discontinued operations | - | 198,324 |
| Total Current Assets | 2,753,062 | 2,093,123 |
| Property, plant and equipment, net | 277,009 | 65,214 |
| Intangible assets and capitalized software, net | 8,962,688 | - |
| Security deposits | 10,531 | 49,029 |
| Operating lease right-of-use assets | 529,623 | 1,051,815 |
| Noncurrent assets of discontinued operations | - | 450,845 |
| Total Assets | $12,532,913 | $3,710,026 |
| Liabilities and Shareholders’ Equity | ||
| Current Liabilities | ||
| Accounts payable | 2,082,054 | 527,984 |
| Accrued liabilities | 400,987 | 271,230 |
| Other current liabilities | 70,310 | 67,517 |
| Contingent funding liabilities | 1,246,346 | 108,036 |
| Lease liabilities – current portion | 139,705 | 196,872 |
| Notes payable – current portion | 6,530,000 | 166,667 |
| Warrant liability | 736,953 | 588,533 |
| Purchase price payable | 350,000 | - |
| Current liabilities of discontinued operations | - | 219,952 |
| Total Current liabilities | 11,556,355 | 2,146,791 |
| Long Term Liabilities | ||
| Lease liabilities – net of current portion | 409,205 | 887,035 |
| Notes payable | 25,000 | 333,333 |
| Total Liabilities | 11,990,560 | 3,367,159 |
| Stockholders’ Equity | ||
| Series A preferred stock, $0.00001 par value; 9,211,246 shares authorized; none issued and outstanding as of December 31, 2023 and December 31, 2022 | - | - |
| Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 outstanding as of December 31, 2023, and none as December 31, 2022 | - | - |
| Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 290 issued and outstanding as of December 31, 2023, and none as of December 31, 2022 | - | - |
| Common stock, $0.00001 par value; 100,000,000 shares authorized; 905,008, and 626,247 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 9 | 6 |
| Additional paid-in capital | 33,788,284 | 20,482,666 |
| Retained deficit | (33,245,940) | (19,719,536) |
| Total TRxADE Health, Inc stockholders’ equity | 542,353 | 763,136 |
| Non-controlling interest in subsidiary | - | (420,269) |
| Total stockholders’ equity | 542,353 | 342,867 |
| Total Liabilities and Stockholders’ Equity | $12,532,913 | $3,710,026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.